Why the study?
Does combined treatment with statins and n-3 PUFA improve survival and reduce major cardiovascular events in patients discharged for acute myocardial infarction compared to statins alone?
Does combined treatment with statins and n-3 PUFA improve survival and reduce major cardiovascular events in patients discharged for acute myocardial infarction compared to statins alone?
In patients discharged after an acute myocardial infarction, the addition of n-3 PUFA to statin therapy is associated with significantly improved survival and reduced incidence of atrial fibrillation and heart failure.
Answers are grounded in this paper and cite their sources.
May not yet support adding n-3 PUFA to statins post-MI; leaves open confirmation of survival benefit in RCTs.
BACKGROUND: Combined treatment (CT) with statins and polyunsaturated fatty acids (n-3 PUFA) resulted in a reduction of death and major cardiovascular events when administered after a myocardial infarction (MI). However, recent data suggests that CT may be ineffective because patients are currently treated aggressively and the risk may not be further decreased. We aimed to study the prevalence and the results on major outcomes with CT among patients discharged with a MI in Italy. METHODOLOGY/PRINCIPAL FINDINGS: Retrospective cohort study that used linked hospital discharge, prescription databases and vital statistics containing information on 14,704 patients who were discharged for MI between 1/2003 and 12/2003 in 117 hospitals in Italy. All analyses were time-dependent and adjusted for major confounders. Sensibility and paired matched analysis were conducted to further verify main results. A total of 11,532 (78.4%) filled a prescription for a statin. Of these, 4302 (37.3%) were on CT. There were 45,528 patients/years of follow-up. As compared with statins alone, CT was associated with an adjusted higher survival rate (HR = 0.59 [0.52-0.66], p<0.001), survival free of atrial fibrillation (HR = 0.78 [0.71-0.86], p<0.001) and survival free of new heart failure development (HR = 0.81 [0.74-0.88], p<0.001), but not with re-infarction (HR = 0.94 [0.86-1.02], p<0.127). Clinically this means that between 2 to 3 fewer events for each 100 patients/year were obtained in the group under CT. CONCLUSIONS/SIGNIFICANCE: Among a representative sample of patients discharged with MI in Italy, we observed clinically significant synergism between the effects of statins and n-3 PUFA for most cardiovascular outcomes, including all cause mortality.
No takes yet. Share an insight, caveat, or question.
Macchia et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: